Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
BG Medicine, Inc. (NASDAQ: BGMD) shares declined 13.39 percent to close at $0.97 a share Friday. The stock traded between $0.92 and $1.09 on volume of 753,169 shares traded. Analysts at Robert W. Baird have recently downgraded the company’s rating to “neutral” from “outperform”. Shares of BG Medicine have fallen approximately 58.0 percent year-to-date.
Find out more about BG Medicine including full access to the free equity report at:
www.RDInvesting.com/BGMD
Corcept Therapeutics Inc. (NASDAQ: CORT) shares declined 10.05 percent to close at $1.70 a share Friday. The stock traded between $1.68 and $1.97 on volume of 532,315 shares traded. Analysts at Janney have recently downgraded the company’s rating to “neutral” from “buy”. Shares of Corcept Therapeutics have gained approximately 18.0 percent year-to-date.
Find out more about Corcept Therapeutics including full access to the free equity report at:
www.RDInvesting.com/CORT
Emulex Corporation (NYSE: ELX) shares increased 1.17 percent to close at $7.78 a share Friday. The stock traded between $7.25 and $7.80 on volume of 1.59 million shares traded. Analysts at Needham have recently downgraded the company’s rating to “hold” from “buy”. Shares of Emulex have gained approximately 6.5 percent year-to-date.
Find out more about Emulex including full access to the free equity report at:
www.RDInvesting.com/ELX
Tetra Tech, Inc. (NASDAQ: TTEK) shares declined 1.50 percent to close at $23.02 a share Friday. The stock traded between $22.64 and $23.23 on volume of 355,191 shares traded. Analysts at Robert W. Baird have recently downgraded the company’s rating to “neutral” from “outperform”. Shares of Tetra Tech have fallen approximately 13.0 percent year-to-date.
Find out more about Tetra Tech including full access to the free equity report at:
www.RDInvesting.com/TTEK
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
[email protected]